Literature DB >> 30257034

Ewing-like sarcoma: An emerging family of round cell sarcomas.

Samuele Renzi1, Nathaniel D Anderson2, Nicholas Light2, Abha Gupta1,3,4.   

Abstract

Ewing-like sarcomas are an emerging subgroup of small round blue cell sarcomas that share various degrees of morphological, immunohistochemical, molecular, and clinical similarity with Ewing sarcoma. Despite these similarities, Ewing-like sarcomas lack the pathognomonic molecular hallmark of Ewing sarcoma: A translocation between a gene of the RNA-binding TET family (EWSR1 or FUS) with a gene of the ETS-transcription family ( FLI1, ERG, ETV1, ETV4, or FEV). Recently, increased use of modern molecular methods based on next-generation sequencing have enabled the identification of distinct subgroups within this previously uncharacterized group of Ewing-like sarcomas based on the discovery of novel molecular driving events. The focus of this review is to provide an update on the main subcategories of Ewing-like sarcomas discovered to date: CIC-rearranged sarcomas, BCOR-rearranged sarcomas, sarcomas with a rearrangement between EWSR1 and a non-ETS family gene, and the substantial fraction of tumors which remain uncharacterized by molecular methods. There is increasing evidence that these tumors represent stand-alone entities with unique characteristics rather than simply a subgroup of Ewing sarcoma; thus, the question of the best therapeutic approach for these often aggressive sarcomas remains of primary importance. Ultimately, large collaborative efforts will be necessary to better determine the characteristics of this rare, heterogeneous family of tumors.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  gene fusions; molecular diagnostics; pediatric oncology; sarcoma

Mesh:

Substances:

Year:  2018        PMID: 30257034     DOI: 10.1002/jcp.27558

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  21 in total

1.  [Report of the Bone, Joint, and Soft Tissue Pathology Working Group : DGP Conference on 4 June 2020].

Authors:  S Scheil-Bertram; E Wardelmann
Journal:  Pathologe       Date:  2020-12       Impact factor: 1.011

Review 2.  ERK signalling: a master regulator of cell behaviour, life and fate.

Authors:  Hugo Lavoie; Jessica Gagnon; Marc Therrien
Journal:  Nat Rev Mol Cell Biol       Date:  2020-06-23       Impact factor: 94.444

3.  Molecular Approaches to Diagnosis in Ewing Sarcoma: Targeted RNA Sequencing.

Authors:  Carmen Salguero-Aranda; Juan Diaz-Martin
Journal:  Methods Mol Biol       Date:  2021

Review 4.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

5.  Fatal course of undetected Ewing-like sarcoma in a 9-year-old boy with uncharacteristic clinical presentation.

Authors:  Walther Gotsmy; Bettina Neumayer; Theo Kraus; Barbara Zellinger; Daniel Neureiter; Fabio Monticelli; Harald Meyer; Peter Hofer
Journal:  Forensic Sci Med Pathol       Date:  2021-11-15       Impact factor: 2.456

Review 6.  Systemic therapy in pediatric-type soft-tissue sarcoma.

Authors:  K M Ingley; S Cohen-Gogo; A A Gupta
Journal:  Curr Oncol       Date:  2020-02-01       Impact factor: 3.677

7.  Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden.

Authors:  Peter Peneder; Adrian M Stütz; Didier Surdez; Manuela Krumbholz; Sabine Semper; Mathieu Chicard; Nathan C Sheffield; Gaelle Pierron; Eve Lapouble; Marcus Tötzl; Bekir Ergüner; Daniele Barreca; André F Rendeiro; Abbas Agaimy; Heidrun Boztug; Gernot Engstler; Michael Dworzak; Marie Bernkopf; Sabine Taschner-Mandl; Inge M Ambros; Ola Myklebost; Perrine Marec-Bérard; Susan Ann Burchill; Bernadette Brennan; Sandra J Strauss; Jeremy Whelan; Gudrun Schleiermacher; Christiane Schaefer; Uta Dirksen; Caroline Hutter; Kjetil Boye; Peter F Ambros; Olivier Delattre; Markus Metzler; Christoph Bock; Eleni M Tomazou
Journal:  Nat Commun       Date:  2021-05-28       Impact factor: 14.919

Review 8.  In vitro three-dimensional cell cultures for bone sarcomas.

Authors:  Javier Munoz-Garcia; Camille Jubelin; Aurélie Loussouarn; Matisse Goumard; Laurent Griscom; Axelle Renodon-Cornière; Marie-Françoise Heymann; Dominique Heymann
Journal:  J Bone Oncol       Date:  2021-07-06       Impact factor: 4.072

9.  Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).

Authors:  Eric S Schafer; Rachel E Rau; Stacey L Berg; Xiaowei Liu; Charles G Minard; Alexander J R Bishop; J Carolina Romero; M John Hicks; Marvin D Nelson; Stephan Voss; Joel M Reid; Elizabeth Fox; Brenda J Weigel; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2019-11-14       Impact factor: 3.838

10.  Xeroderma Pigmentosum group D suppresses proliferation and promotes apoptosis of HepG2 cells by downregulating ERG expression via the PPARγ pathway.

Authors:  Yue He; Wenqiang Tao; Chao Shang; Chan Qi; Dexiang Ji; Wei Lu; Guoan Chen
Journal:  Int J Exp Pathol       Date:  2021-05-15       Impact factor: 2.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.